Begoña Quintana-Villamandos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Begoña Quintana-Villamandos has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Ana Arnalich-Montiel
Department of Pharmacology and Toxicology, Faculty of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
3 shared publications - Pilar Rodríguez-Rodríguez
Department of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, 28029 Madrid, Spain
3 shared publications - Silvia Magdalena Arribas
Department of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, 28029 Madrid, Spain
3 shared publications - Alba Burgos-Santamaría
Department of Anesthesia and Intensive Care, Gregorio Marañón University Hospital, Madrid, Spain (Burgos-Santamaría A, Arnalich-Montiel A, Barrio-Pérez IM, Fernández-Riveira C, Quintana-Villamandos B)
2 shared publications - Laia Pazó-Sayós
Department of Anesthesiology, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo 46, 28007 Madrid, Spain
2 shared publications - Raquel Martín-Oropesa
Department of Anesthesiology, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo 46, 28007 Madrid, Spain
2 shared publications
Latest Publications
- 28 September 2026
- Published by Wolters Kluwer Health in Anesthesiology
Intraoperative blood pressure targeting in noncardiac surgery: a Bayesian random-effects meta-analysis of randomized trials
Background: Whether protocolized intraoperative arterial pressure-targeting strategies provide incremental benefit beyond contemporary usual care remains uncertain. We performed a Bayesian meta-analysis of randomized trials in major noncardiac surgery. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 5, 2026, with additional literature surveillance through June 29, 2026. Randomized trials comparing protocolized intraoperative arterial pressure-targeting strategies with usual care or lower-pressure approaches were included. The primary outcome was all-cause mortality; secondary outcomes were acute kidney injury (AKI) and myocardial injury after noncardiac surgery (MINS). Bayesian random-effects meta-analysis was prespecified as the primary analytical framework, with confirmatory frequentist analyses. Results: Fifteen randomized trials met the inclusion criteria. Mortality (13 trials) remained centered around an OR of 1.00 (frequentist OR 1.00, 95% CI 0.83–1.21; Bayesian median OR 1.00, 95% CrI 0.73–1.38), with wide Bayesian prediction intervals (OR 0.56–1.78). AKI (14 trials) showed the most favorable estimates (frequentist OR 0.87, 95% CI 0.73–1.03; Bayesian median OR 0.88, 95% CrI 0.70–1.05), but estimates remained compatible with no clinically important benefit, heterogeneity was moderate, and leave-one-out analyses, excluding each trial in turn, showed sensitivity to individual-trial exclusion. MINS (8 trials) likewise remained compatible with no treatment effect (frequentist OR 1.04, 95% CI 0.93–1.15; Bayesian median OR 1.05, 95% CrI 0.90–1.26). Exploratory analyses suggested that any potential renal benefit may depend on the broader hemodynamic context in which arterial pressure targets are implemented. Conclusions: Protocolized intraoperative arterial pressure-targeting strategies did not demonstrate a consistent incremental benefit over contemporary usual care in major noncardiac surgery. Mortality and MINS remained compatible with no treatment effect. Although AKI showed the most favorable estimates, the evidence remained uncertain, was sensitive to individual-trial exclusion, and should be interpreted cautiously.
- 28 September 2026
- Published by Wolters Kluwer Health in Anesthesiology
Intraoperative blood pressure targeting in noncardiac surgery: a Bayesian random-effects meta-analysis of randomized trials
Background: Whether protocolized intraoperative arterial pressure-targeting strategies provide incremental benefit beyond contemporary usual care remains uncertain. We performed a Bayesian meta-analysis of randomized trials in major noncardiac surgery. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 5, 2026, with additional literature surveillance through June 29, 2026. Randomized trials comparing protocolized intraoperative arterial pressure-targeting strategies with usual care or lower-pressure approaches were included. The primary outcome was all-cause mortality; secondary outcomes were acute kidney injury (AKI) and myocardial injury after noncardiac surgery (MINS). Bayesian random-effects meta-analysis was prespecified as the primary analytical framework, with confirmatory frequentist analyses. Results: Fifteen randomized trials met the inclusion criteria. Mortality (13 trials) remained centered around an OR of 1.00 (frequentist OR 1.00, 95% CI 0.83–1.21; Bayesian median OR 1.00, 95% CrI 0.73–1.38), with wide Bayesian prediction intervals (OR 0.56–1.78). AKI (14 trials) showed the most favorable estimates (frequentist OR 0.87, 95% CI 0.73–1.03; Bayesian median OR 0.88, 95% CrI 0.70–1.05), but estimates remained compatible with no clinically important benefit, heterogeneity was moderate, and leave-one-out analyses, excluding each trial in turn, showed sensitivity to individual-trial exclusion. MINS (8 trials) likewise remained compatible with no treatment effect (frequentist OR 1.04, 95% CI 0.93–1.15; Bayesian median OR 1.05, 95% CrI 0.90–1.26). Exploratory analyses suggested that any potential renal benefit may depend on the broader hemodynamic context in which arterial pressure targets are implemented. Conclusions: Protocolized intraoperative arterial pressure-targeting strategies did not demonstrate a consistent incremental benefit over contemporary usual care in major noncardiac surgery. Mortality and MINS remained compatible with no treatment effect. Although AKI showed the most favorable estimates, the evidence remained uncertain, was sensitive to individual-trial exclusion, and should be interpreted cautiously.
- Open Access
- 24 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5799
Protective Effect of Esmolol on the Hypertensive Aortic Wall Persists After Withdrawal of Short-Term Treatment
Background: Our research group has previously demonstrated the protective effect of short-term treatment with esmolol on large artery remodeling. However, whether this beneficial effect persists after treatment withdrawal remains unknown. Therefore, the aim of the present study was to investigate whether regression of thoracic aorta remodeling after a short-term esmolol treatment persists following drug withdrawal. Methods: Adult male spontaneously hypertensive rats (SHRs) received either esmolol (300 µg/kg/min) or vehicle (saline solution) by continuous infusion for 48 h. Following treatment, animals were evaluated either immediately (SHR-E 48 h group) or after withdrawal periods of 7 days (SHR-E 7 d group) or 1 month (SHR-E 1 m group). Hemodynamic parameters, thoracic aorta geometry, extracellular matrix composition (elastin and collagen), and the passive mechanical response of the arterial wall (β parameter) were assessed in all animals. Results: Forty-eight hours of esmolol treatment significantly reduced blood pressure and attenuated thoracic aortic wall thickness, external diameter, cross-sectional area, collagen content and elastic fiber density. Additionally, passive mechanical testing showed a significant reduction in the β parameter, indicating improved arterial compliance after treatment. Remarkably, these structural and mechanical benefits persisted for up to one month after withdrawal, despite the return of blood pressure to hypertensive levels. Conclusions: Protective effect of esmolol on aortic remodeling is persistent after treatment withdrawal in SHRs, perhaps independent of blood pressure.
- 24 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5799
Open AccessProtective Effect of Esmolol on the Hypertensive Aortic Wall Persists After Withdrawal of Short-Term Treatment
Background: Our research group has previously demonstrated the protective effect of short-term treatment with esmolol on large artery remodeling. However, whether this beneficial effect persists after treatment withdrawal remains unknown. Therefore, the aim of the present study was to investigate whether regression of thoracic aorta remodeling after a short-term esmolol treatment persists following drug withdrawal. Methods: Adult male spontaneously hypertensive rats (SHRs) received either esmolol (300 µg/kg/min) or vehicle (saline solution) by continuous infusion for 48 h. Following treatment, animals were evaluated either immediately (SHR-E 48 h group) or after withdrawal periods of 7 days (SHR-E 7 d group) or 1 month (SHR-E 1 m group). Hemodynamic parameters, thoracic aorta geometry, extracellular matrix composition (elastin and collagen), and the passive mechanical response of the arterial wall (β parameter) were assessed in all animals. Results: Forty-eight hours of esmolol treatment significantly reduced blood pressure and attenuated thoracic aortic wall thickness, external diameter, cross-sectional area, collagen content and elastic fiber density. Additionally, passive mechanical testing showed a significant reduction in the β parameter, indicating improved arterial compliance after treatment. Remarkably, these structural and mechanical benefits persisted for up to one month after withdrawal, despite the return of blood pressure to hypertensive levels. Conclusions: Protective effect of esmolol on aortic remodeling is persistent after treatment withdrawal in SHRs, perhaps independent of blood pressure.
- Open Access
- 25 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1660359
Influence of the type of volatile anesthetic on the development of acute kidney injury after endovascular repair of aortic aneurysm: a randomized controlled trial (DESEVAR study)
Acute kidney injury (AKI) frequently occurs after endovascular aortic aneurysm repair (EVAR), leading to significant morbidity and mortality. It is associated with contrast administration, hypovolemia, arterial microembolization due to renal artery manipulation, ischemia–reperfusion syndrome, and other patient comorbidities. However, little is known about the effect of volatile anesthetics on the development of AKI in this context. Therefore, we aimed to investigate renal function in patients anesthetized with desflurane or sevoflurane for EVAR. For this, we conducted a single-center randomized clinical trial involving 80 patients scheduled for elective EVAR under general anesthesia. Patients were randomly assigned to the desflurane or sevoflurane anesthesia group. Biochemical variables of kidney function and biomarkers for AKI were studied at three different time points: before surgery, after surgery, and 24 h after surgery. Plasma creatinine, cystatin C, estimated glomerular filtration, uric acid, and kidney injury molecule-1 did not significantly change between both groups. A mixed linear model demonstrated a significant interaction (p = 0.01) of plasma neutrophil gelatinase-associated lipocalin (NGAL) between sevoflurane and desflurane. Both groups showed a progressive increase in plasma NGAL (sevoflurane 3.713 ng/mL, p < 0.001 and desflurane 1.774 ng/mL, p < 0.001) when comparing the moment before surgery with respect to 24 h after surgery. However, sevoflurane caused a higher plasma NGAL concentration than desflurane after 24 h of surgery (8.66 ± 5.09 ng/mL vs. 6.51 ± 3.86 ng/mL, P = 0.03). Desflurane was associated with a lower postoperative AKI than sevoflurane in patients undergoing EVAR. Further research is required to corroborate our results and evaluate the clinical importance. Trial registration: EudraCT: 2016-003906-16; ClinicalTrials.gov: NCT03917186.
- 25 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1660359
Open AccessInfluence of the type of volatile anesthetic on the development of acute kidney injury after endovascular repair of aortic aneurysm: a randomized controlled trial (DESEVAR study)
Acute kidney injury (AKI) frequently occurs after endovascular aortic aneurysm repair (EVAR), leading to significant morbidity and mortality. It is associated with contrast administration, hypovolemia, arterial microembolization due to renal artery manipulation, ischemia–reperfusion syndrome, and other patient comorbidities. However, little is known about the effect of volatile anesthetics on the development of AKI in this context. Therefore, we aimed to investigate renal function in patients anesthetized with desflurane or sevoflurane for EVAR. For this, we conducted a single-center randomized clinical trial involving 80 patients scheduled for elective EVAR under general anesthesia. Patients were randomly assigned to the desflurane or sevoflurane anesthesia group. Biochemical variables of kidney function and biomarkers for AKI were studied at three different time points: before surgery, after surgery, and 24 h after surgery. Plasma creatinine, cystatin C, estimated glomerular filtration, uric acid, and kidney injury molecule-1 did not significantly change between both groups. A mixed linear model demonstrated a significant interaction (p = 0.01) of plasma neutrophil gelatinase-associated lipocalin (NGAL) between sevoflurane and desflurane. Both groups showed a progressive increase in plasma NGAL (sevoflurane 3.713 ng/mL, p < 0.001 and desflurane 1.774 ng/mL, p < 0.001) when comparing the moment before surgery with respect to 24 h after surgery. However, sevoflurane caused a higher plasma NGAL concentration than desflurane after 24 h of surgery (8.66 ± 5.09 ng/mL vs. 6.51 ± 3.86 ng/mL, P = 0.03). Desflurane was associated with a lower postoperative AKI than sevoflurane in patients undergoing EVAR. Further research is required to corroborate our results and evaluate the clinical importance. Trial registration: EudraCT: 2016-003906-16; ClinicalTrials.gov: NCT03917186.
- Open Access
- 7 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10770
OXY-SCORE and Volatile Anesthetics: A New Perspective of Oxidative Stress in EndoVascular Aneurysm Repair—A Randomized Clinical Trial
An aortic aneurysm (AA) is a life-threatening condition. Oxidative stress may be a common pathway linking multiple mechanisms of an AA, including vascular inflammation and metalloproteinase activity. Endovascular aneurysm repair (EVAR) is the preferred surgical approach for AA treatment. During surgery, inflammation and ischemia–reperfusion injury occur, and reactive oxygen species (ROS) play a key role in their modulation. Increased perioperative oxidative stress is associated with higher postoperative complications. The use of volatile anesthetics during surgery has been shown to reduce oxidative stress. Individual biomarkers only partially reflect the oxidative status of the patients. A global indicator of oxidative stress (OXY-SCORE) has been validated in various pathologies. This study aimed to compare the effects of the main volatile anesthetics, sevoflurane and desflurane, on oxidative status during EVAR. Eighty consecutive patients undergoing EVAR were randomized into two groups: sevoflurane and desflurane. Plasma biomarkers of oxidative damage (protein carbonylation and malondialdehyde) and antioxidant defense (total thiols, glutathione, nitrates, superoxide dismutase, and catalase activity) were measured before surgery and 24 h after EVAR. The analysis of individual biomarkers showed no significant differences between the groups. However, the OXY-SCORE was positive in the desflurane group (indicating a shift towards antioxidants) and negative in the sevoflurane group (favoring oxidants) (p < 0.044). Compared to sevoflurane, desflurane had a positive effect on oxidative stress during EVAR. The OXY-SCORE could provide a more comprehensive perspective on oxidative stress in this patient population.
- 7 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10770
Open AccessOXY-SCORE and Volatile Anesthetics: A New Perspective of Oxidative Stress in EndoVascular Aneurysm Repair—A Randomized Clinical Trial
An aortic aneurysm (AA) is a life-threatening condition. Oxidative stress may be a common pathway linking multiple mechanisms of an AA, including vascular inflammation and metalloproteinase activity. Endovascular aneurysm repair (EVAR) is the preferred surgical approach for AA treatment. During surgery, inflammation and ischemia–reperfusion injury occur, and reactive oxygen species (ROS) play a key role in their modulation. Increased perioperative oxidative stress is associated with higher postoperative complications. The use of volatile anesthetics during surgery has been shown to reduce oxidative stress. Individual biomarkers only partially reflect the oxidative status of the patients. A global indicator of oxidative stress (OXY-SCORE) has been validated in various pathologies. This study aimed to compare the effects of the main volatile anesthetics, sevoflurane and desflurane, on oxidative status during EVAR. Eighty consecutive patients undergoing EVAR were randomized into two groups: sevoflurane and desflurane. Plasma biomarkers of oxidative damage (protein carbonylation and malondialdehyde) and antioxidant defense (total thiols, glutathione, nitrates, superoxide dismutase, and catalase activity) were measured before surgery and 24 h after EVAR. The analysis of individual biomarkers showed no significant differences between the groups. However, the OXY-SCORE was positive in the desflurane group (indicating a shift towards antioxidants) and negative in the sevoflurane group (favoring oxidants) (p < 0.044). Compared to sevoflurane, desflurane had a positive effect on oxidative stress during EVAR. The OXY-SCORE could provide a more comprehensive perspective on oxidative stress in this patient population.
- Open Access
- 11 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5252
Comprehensive Management of Stroke: From Mechanisms to Therapeutic Approaches
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are eligible for this time-sensitive treatment. Even though there is still significant room for improvement in the management of this group of patients, up until now there have been no alternative therapies approved for use in clinical practice. However, there is still hope, as clinical research with novel emerging therapies is now generating promising results. These drugs happen to stop or palliate some of the underlying molecular mechanisms involved in cerebral ischemia and secondary brain damage. The aim of this review is to provide a deep understanding of these mechanisms and the pathogenesis of AIS. Later, we will discuss the potential therapies that have already demonstrated, in preclinical or clinical studies, to improve the outcomes of patients with AIS.
- 11 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5252
Open AccessComprehensive Management of Stroke: From Mechanisms to Therapeutic Approaches
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are eligible for this time-sensitive treatment. Even though there is still significant room for improvement in the management of this group of patients, up until now there have been no alternative therapies approved for use in clinical practice. However, there is still hope, as clinical research with novel emerging therapies is now generating promising results. These drugs happen to stop or palliate some of the underlying molecular mechanisms involved in cerebral ischemia and secondary brain damage. The aim of this review is to provide a deep understanding of these mechanisms and the pathogenesis of AIS. Later, we will discuss the potential therapies that have already demonstrated, in preclinical or clinical studies, to improve the outcomes of patients with AIS.
- Open Access
- 17 October 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (10) , 2042
Maintenance over Time of the Effect Produced by Esmolol on the Structure and Function of Coronary Arteries in Hypertensive Heart Diseases
We previously observed that esmolol treatment for 48 h reduced vascular lesions in spontaneously hypertensive rats (SHRs). Therefore, we investigated whether this beneficial effect is persistent after withdrawal. Fourteen-month-old SHRs (SHR-Es) were treated with esmolol (300 μg/kg/min) or a vehicle for 48 h. Two separate groups were also given identical treatment, but they were then monitored for a further 1 week and 1 month after drug withdrawal. We analyzed the geometry and composition of the coronary artery, vascular reactivity and plasma redox status. Esmolol significantly decreased wall thickness (medial layer thickness and cell count), external diameter and cross-sectional area of the artery, and this effect persisted 1 month after drug withdrawal. Esmolol significantly improved endothelium-dependent relaxation by ACh (10−9–10−4 mol/L); this effect persisted 1 week (10−9–10−4 mol/L) and 1 month (10−6–10−4 mol/L) after withdrawal. Esmolol reduced the contraction induced by 5-HT (3 × 10−8–3 × 10−5 mol/L), and this effect persisted 1 week after withdrawal (10−6–3 × 10−5 mol/L). Esmolol increased nitrates and reduced glutathione, and it decreased malondialdehyde and carbonyls; this enhancement was maintained 1 month after withdrawal. This study shows that the effect of esmolol on coronary remodeling is persistent after treatment withdrawal in SHRs, and the improvement in plasma oxidative status can be implicated in this effect.
- 17 October 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (10) , 2042
Open AccessMaintenance over Time of the Effect Produced by Esmolol on the Structure and Function of Coronary Arteries in Hypertensive Heart Diseases
We previously observed that esmolol treatment for 48 h reduced vascular lesions in spontaneously hypertensive rats (SHRs). Therefore, we investigated whether this beneficial effect is persistent after withdrawal. Fourteen-month-old SHRs (SHR-Es) were treated with esmolol (300 μg/kg/min) or a vehicle for 48 h. Two separate groups were also given identical treatment, but they were then monitored for a further 1 week and 1 month after drug withdrawal. We analyzed the geometry and composition of the coronary artery, vascular reactivity and plasma redox status. Esmolol significantly decreased wall thickness (medial layer thickness and cell count), external diameter and cross-sectional area of the artery, and this effect persisted 1 month after drug withdrawal. Esmolol significantly improved endothelium-dependent relaxation by ACh (10−9–10−4 mol/L); this effect persisted 1 week (10−9–10−4 mol/L) and 1 month (10−6–10−4 mol/L) after withdrawal. Esmolol reduced the contraction induced by 5-HT (3 × 10−8–3 × 10−5 mol/L), and this effect persisted 1 week after withdrawal (10−6–3 × 10−5 mol/L). Esmolol increased nitrates and reduced glutathione, and it decreased malondialdehyde and carbonyls; this enhancement was maintained 1 month after withdrawal. This study shows that the effect of esmolol on coronary remodeling is persistent after treatment withdrawal in SHRs, and the improvement in plasma oxidative status can be implicated in this effect.
- 1 December 2019
- Published by Springer Nature in Pharmacological Reports
- Vol. 71 (6) , 1125-1132
Early reversal cardiac with esmolol in hypertensive rats: The role of subcellular organelle phenotype
Our group has previously shown that short-term treatment (48 h) with esmolol reduces left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs). However, we do not know the mechanism that explain this effect. The aim of this study was to assess the role that the subcellular organelle phenotype plays in early cardiac reverse after short-term treatment with esmolol. 14-Month-old male SHRs were randomly assigned to receive esmolol (300 μg/kg/min) (SHR-E) or vehicle (SHR). Age-matched male Wistar-Kyoto rats (WKY) served as controls. After 48 h of treatment, an ultrastructural analysis of heart tissue (left ventricle) was performed. We studied cardiomyocyte ultrastructural remodeling of subcellular organelles by electronic microcopy in all groups. SHR group showed significant morphometric and stereological changes in mitochondria and subcellular organelles (cytoplasm and nucleus, myofibril structure, mitochondria structure, Z-Disk, intercalated disk, T-system and cystern), and also changes in the extracellular matrix (collagen) with respect to WKY group. Esmolol significantly improved the morphology and stereology mitochondrial, reduced the organelle phenotype abnormalities but no produced changes in the extracellular matrix with respect to SHR group. Interesantly, parameters of mitochondria (regularity factor, ellipsoidal form factor and density of volume), and all parameters of subcellular organelles returned to the normality in SHR-E. Our results show that left ventricular hypertrophy reversal after short-term treatment with esmolol is associated with reversal of subcellular organelle phenotype.
- 1 December 2019
- Published by Springer Nature in Pharmacological Reports
- Vol. 71 (6) , 1125-1132
Early reversal cardiac with esmolol in hypertensive rats: The role of subcellular organelle phenotype
Our group has previously shown that short-term treatment (48 h) with esmolol reduces left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs). However, we do not know the mechanism that explain this effect. The aim of this study was to assess the role that the subcellular organelle phenotype plays in early cardiac reverse after short-term treatment with esmolol. 14-Month-old male SHRs were randomly assigned to receive esmolol (300 μg/kg/min) (SHR-E) or vehicle (SHR). Age-matched male Wistar-Kyoto rats (WKY) served as controls. After 48 h of treatment, an ultrastructural analysis of heart tissue (left ventricle) was performed. We studied cardiomyocyte ultrastructural remodeling of subcellular organelles by electronic microcopy in all groups. SHR group showed significant morphometric and stereological changes in mitochondria and subcellular organelles (cytoplasm and nucleus, myofibril structure, mitochondria structure, Z-Disk, intercalated disk, T-system and cystern), and also changes in the extracellular matrix (collagen) with respect to WKY group. Esmolol significantly improved the morphology and stereology mitochondrial, reduced the organelle phenotype abnormalities but no produced changes in the extracellular matrix with respect to SHR group. Interesantly, parameters of mitochondria (regularity factor, ellipsoidal form factor and density of volume), and all parameters of subcellular organelles returned to the normality in SHR-E. Our results show that left ventricular hypertrophy reversal after short-term treatment with esmolol is associated with reversal of subcellular organelle phenotype.